SCHEMBL7873334

SCHEMBL7873334

CN(C)Cc1ccc(Oc2ccc3cc(C(=O)N(C)C(=N)N)[nH]c3c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.50
MEN1 O00255 3/20 0.50
RXFP1 Q9HBX9 2/20 0.50
FLT3 P36888 3/20 0.40
PLG P00747 1/20 0.40
PLAU P00749 1/20 0.40
PDGFRB P09619 1/20 0.38
PDGFRA P16234 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
ROCK2 O75116 1/20 0.37
ROCK1 Q13464 1/20 0.37
XDH P47989 1/20 0.37
KDM4E B2RXH2 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7884237 0.92 MEN1 (0.52) KMT2AMEN1RXFP1FLT3PDGFRB
SCHEMBL7881184 0.91 KMT2A (0.47) KMT2AMEN1RXFP1FLT3PLG
SCHEMBL7877806 0.90 KMT2A (0.45) KMT2AMEN1RXFP1FLT3PLG
SCHEMBL7877731 0.89 MEN1 (0.48) KMT2AMEN1RXFP1FLT3PLG
SCHEMBL7873591 0.88 KMT2A (0.45) KMT2AMEN1RXFP1FLT3PLG
SCHEMBL7882065 0.88 KMT2A (0.53) KMT2AMEN1RXFP1FLT3PLG
SCHEMBL7884561 0.86 MEN1 (0.44) KMT2AMEN1RXFP1FLT3PLG
SCHEMBL7884349 0.86 KMT2A (0.43) KMT2AMEN1RXFP1FLT3PLG
SCHEMBL7885067 0.86 KMT2A (0.43) KMT2AMEN1RXFP1FLT3PLG
SCHEMBL7880873 0.85 RXFP1 (0.43) KMT2AMEN1RXFP1FLT3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed